The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.
GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback